Subcutaneous versus Intramuscular Depot Methoxyprogesterone Acetate: A Comparative Review
review
OA: gold
CC0
⤵ 4 in-corpus citations
AI-generated summary
This review compares subcutaneous and intramuscular depot medroxyprogesterone acetate, finding the newer subcutaneous formulation equally effective but with fewer side effects for contraception and endometriosis pain management.
One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works
Abstract
Depot medroxyprogesterone acetate (DMPA; Depo-Provera) is a highly effective and convenient contraceptive method that has been used worldwide for many decades. Recently, a new lower dose of DMPA, administered as a subcutaneous injection, has been approved for use in the USA as a contraceptive and a treatment for pain associated with endometriosis. The newer formulation has a similar efficacy to the older version and, more importantly, has fewer side effects, with improved user tolerability. Similar to the intramuscular DMPA injection (Depo-Provera intramuscular or contraceptive injection), the subcutaneous injection provides effective contraceptive and pain-management therapy for endometriosis, with a 3-monthly injectable protocol for women who seek long-term and reversible contraception without the need for a daily pill or a more frequent dosing regimen.
My notes (saved in your browser only)
Condition tags
Citation neighborhood (sparse)
Too few in-corpus citations on either side for a chart; here are the lists.
Cites (3)
- Subcutaneous depot medroxyprogesterone acetate versus leuprolide acetate in the treatment of endometriosis-associated pain 2005
- Evaluation and management of women with endometriosis 2003
- [Conservative surgery combined with depot medroxyprogesterone acetate in treatment of moderate or severe endometriosis]. 2005
Cited by (4)
- Pharmaceuticals targeting signaling pathways of endometriosis as potential new medical treatment: A review 2021
- Progestin Therapy in Endometriosis 2015
- Contraception and endometriosis: challenges, efficacy, and therapeutic importance 2015
- Hormonal Therapy in Endometriosis and Adenomyosis: Progestins 2022
References (29)
- [Conservative surgery combined with depot medroxyprogesterone acetate in treatment of moderate or severe endometriosis]. via openalex
- Evaluation and management of women with endometriosis via openalex
- Subcutaneous depot medroxyprogesterone acetate versus leuprolide acetate in the treatment of endometriosis-associated pain via openalex
- W1983711108 via openalex
- W1986175627 via openalex
- W1995127183 via openalex
- W2037039941 via openalex
- W2042043425 via openalex
- W2043640947 via openalex
- W2060267578 via openalex
- W2069998169 via openalex
- W2071662250 via openalex
- W2072195133 via openalex
- W2073953824 via openalex
- W2076495582 via openalex
- W2076720074 via openalex
- W2077556384 via openalex
- W2114111686 via openalex
- W2115274031 via openalex
- W2149574073 via openalex
- W2155119058 via openalex
- W2162204795 via openalex
- W2168588656 via openalex
- W2169015769 via openalex
- W4231103938 via openalex
- W56973596 via openalex
- W4233187059 via openalex
- W159203288 via openalex
- W1970693625 via openalex
Cited by (4)
- Hormonal Therapy in Endometriosis and Adenomyosis: Progestins 2022
- Pharmaceuticals targeting signaling pathways of endometriosis as potential new medical treatment: A review 2021
- Progestin Therapy in Endometriosis 2015
- Contraception and endometriosis: challenges, efficacy, and therapeutic importance 2015
Source provenance
- europepmc
- last seen: 2026-09-01T06:12:48.306406+00:00
- openalex
- last seen: 2026-06-04T00:00:01.174412+00:00
- pubmed
- last seen: 2026-05-13T22:15:23.967219+00:00
License: CC0
· commercial use OK